Pharmacokinetics of terodiline in human volunteers. 1982

B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten

The pharmacokinetics of terodiline HCl was studied in nine healthy volunteers given 12.5 mg i.v. and p.o. or 20 mg i.v. and 25 mg p.o. on two different occasions. The serum concentrations were measured by gas chromatography--mas spectrometry, using deuterated terodiline HCl as the internal standard. After i.v. administration the kinetics could be described by a two-compartment model with a mean distribution half life of 0.3 h and a mean elimination half life of 63 h. The serum clearance and apparent volume of distribution varied about 4-fold with mean values of 4.8 1/h and 417 1, respectively. After oral administration, the mean half life of absorption was 0.7 h and that of elimination 65 h. The absolute bioavailability varied between 64% and 105% with a mean of 92%. The long serum half life of terodiline should permit its once daily administration.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D002082 Butylamines Isomeric amines of butane, where an amino group replaces a hydrogen on one of the four carbons. They include isobutylamine, n-Butylamine, sec-Butylamine, and tert-Butylamine.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
September 1993, Pharmacology & toxicology,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
March 1984, Toxicology and applied pharmacology,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
April 1982, Journal of pharmaceutical sciences,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
January 1983, Chemotherapy,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
September 2004, Archives of pharmacal research,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
September 1980, The Journal of antimicrobial chemotherapy,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
March 1980, Toxicology and applied pharmacology,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
January 1984, European journal of rheumatology and inflammation,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
January 1988, European journal of clinical pharmacology,
B Karlén, and K E Andersson, and G Ekman, and S Strömberg, and U Ulmsten
January 1991, Human & experimental toxicology,
Copied contents to your clipboard!